沉香化滞丸联合西药治疗肝郁气滞型胃动力不足42例临床观察

Clinical Observation on 42 Cases of Liver Depression and Qi Stagnation Type Gastric Dyskinesia Treated with Chenxiang Huazhi Pill Combined with Western Medicine

目的:探究沉香化滞丸联合西药治疗肝郁气滞型胃动力不足患者的治疗效果以及对中医证候积分、血清脑-肠轴相关因子水平的影响。方法:收集84例胃动力不足患者临床资料,根据治疗方法不同分为两组,对照组42例采用西药治疗,观察组42例于对照组基础上增用沉香化滞丸。比较两组治疗前与治疗1个月后中医证候积分、血清脑-肠轴相关因子[神经肽S受体1(NPSR1)降钙素基因相关肽(CGRP)、血管活性肠肽(VIP)、生长抑素(SS)]水平、治疗1个月治疗效果,统计不良反应及复发情况。结果:治疗1个月后,观察组中医证候主症、次症、总积分均低于对照组(P<0.05),观察组NPSRI水平高于对照组,CGRP、VIP、SS水平低于对照组(P<0.05);观察组复发率为4.76%,明显低于对照组的19.05%(P<0.05);两组不良反应发生率比较(4.76%和9.52%),差异无统计学意义(P>0.05);观察组总有效率为97.62%,高于对照组的80.95%(P<0.05)。结论:沉香化滞丸联合西药可调节肝郁气滞型胃动力不足患者脑-肠轴相关因子,有效缓解患者症状,增强临床疗效,降低复发风险,且安全性较高。

Objective To investigate the therapeutic effect of Chenxiang Huazhi Pill combined with western medicines in treating patients with gastric dyskinesia of liver depression and qi stagnation type,as well as the effects on Chinese medicine evidence points and serum brain-intestinal axis-related factor levels.Methods The clinical data of 84 patients with gastric motility deficiency were collected and divided into two groups according to different treatment methods.42 cases in the control group were treated with conventional western medicine,and 42 cases in the observation group were treated with Chenxiang Huazhi pills on the basis of the control group.The TCM syndrome score,serum brain gut axis related factors[neuropeptide S receptor 1(npsr1),calcitonin gene-related peptide(CGRP),vasoactive intestinal peptide(VIP),somatostatin(SS)]levels,the therapeutic effect of the two groups before treatment and 1 month after treatment were compared,and the adverse reactions and recurrence were counted.Results After one month of treatment,the main symptoms,secondary symptoms and total score of TCM syndrome in the observation group were lower than those in the control group(P<0.05);the npsri level of the observation group was higher than that of the control group,and the CGRP,VIP and SS levels of the observation group were lower than those of the control group(P<0.05);the recurrence rate in the observation group was 4.76%,which was significantly lower than 19.05%in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(4.76%vs 9.52%)(P>0.05);the total effective rate of the observation group was 97.62%,which was higher than the 80.95%of the control group(P<0.05).Conclusion Chenxiang Huazhi Pill combined with western medicines can regulate brain-intestinal axis-related factors in patients with gastric dyskinesia due to liver depression and qi stagnation,effectively alleviate patients symptoms,enhance the clinical efficacy,reduce the risk of recurrence,and have a high safety profile.